Copy

Neurology
Issue 02  |   November 2016
ESL Biosciences, in partnership with Euroimmun AG, offer the most comprehensive range
of diagnostic products for Neurology
NMOSD Screen 1

Autoantibodies against Aquaporin-4 (AQP-4) and Myelin-Oligodendrocyte Glycoprotein (MOG) can be used for differential diagnosis.

Autoantibodies against Aquaporin-4 (AQP-4) or Myelin-Oligodendrocyte Glycoprotein (MOG) are detectable in demyelinating diseases of the central nervous system.  MOG autoantibodies are mostly found in pediatric patients.

Early differentiation between demyelinisation associated with AQP-4-IgG or MOG-IgG can help decide on therapeutic measures.  This is useful with patients suffering from Neuromyelitis optica spectrum disorders (NMOSD) and patients with multiple sclerosis (MS). 

More specifically, patients with MOG-IgG tend to have a single or a lower number of disease attacks and usually demonstrate better recovery from the attack. MOG-IgG seropositive patients are usually marked by a better outcome in comparison with AQP4-IgG seropositive patients regardless of the course of the disease.  

NMOSD Screen 1:
Differential diagnosis of:

  • Multiple sclerosis
  • Acute disseminated encephalomyelitis (ADEM)
  • AQP-4-seronegative NMSOD
~1/3 of AQP-4-seronegative patients have a positive serological result for MOG.

Order numbers:
FA-1128-1005-1
FA-1128-1010-1
Test instructions are available upon request
View the publication "Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease" (Hoftberger et al)
View the publication "Antibody biomarkers in CNS demyelinating diseases -a long and winding road" (Berger et al)
NZ
NZ
Australia
Australia
Website
Website
Twitter
Twitter
Facebook
Facebook
LinkedIn
LinkedIn
Google+
Google+
Copyright © 2016 ESL Biosciences Australia (2012) Pty Ltd. All rights reserved.
unsubscribe from this list  |  update subscription preferences